The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Phosphodiesterase (PDE) inhibitors Market Research Report 2025
Synopsis
A phosphodiesterase inhibitor is a drug that blocks one or more of the five subtypes of the enzyme phosphodiesterase (PDE), thereby preventing the inactivation of the intracellular second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) by the respective PDE subtype(s).
The global Phosphodiesterase (PDE) inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
PDE inhibitor drugs are also used to treat various other medical conditions such as autoimmune indications, ulcerative colitis, and others. However, the increasing incidence of ED across the world will boost the global phosphodiesterase inhibitors market growth during the forecast period.
This report aims to provide a comprehensive presentation of the global market for Phosphodiesterase (PDE) inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Phosphodiesterase (PDE) inhibitors.
Report Scope
The Phosphodiesterase (PDE) inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Liter) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Phosphodiesterase (PDE) inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Phosphodiesterase (PDE) inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer AG
Eli Lilly and Co.
GlaxoSmithKline Plc
Pfizer Inc.
Vivus Inc.
Segment by Type
PDE1 Selective Inhibitors
PDE2 Selective Inhibitors
PDE3 Selective Inhibitors
PDE4 selective inhibitors
PDE5 selective inhibitors
PDE7 selective inhibitors
PDE10 selective inhibitors
Segment by Application
Oral
Topical
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Phosphodiesterase (PDE) inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Phosphodiesterase (PDE) inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
A phosphodiesterase inhibitor is a drug that blocks one or more of the five subtypes of the enzyme phosphodiesterase (PDE), thereby preventing the inactivation of the intracellular second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) by the respective PDE subtype(s).
The global Phosphodiesterase (PDE) inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
PDE inhibitor drugs are also used to treat various other medical conditions such as autoimmune indications, ulcerative colitis, and others. However, the increasing incidence of ED across the world will boost the global phosphodiesterase inhibitors market growth during the forecast period.
This report aims to provide a comprehensive presentation of the global market for Phosphodiesterase (PDE) inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Phosphodiesterase (PDE) inhibitors.
Report Scope
The Phosphodiesterase (PDE) inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Liter) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Phosphodiesterase (PDE) inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Phosphodiesterase (PDE) inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer AG
Eli Lilly and Co.
GlaxoSmithKline Plc
Pfizer Inc.
Vivus Inc.
Segment by Type
PDE1 Selective Inhibitors
PDE2 Selective Inhibitors
PDE3 Selective Inhibitors
PDE4 selective inhibitors
PDE5 selective inhibitors
PDE7 selective inhibitors
PDE10 selective inhibitors
Segment by Application
Oral
Topical
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Phosphodiesterase (PDE) inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Phosphodiesterase (PDE) inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Phosphodiesterase (PDE) inhibitors Market Overview
1.1 Product Overview and Scope of Phosphodiesterase (PDE) inhibitors
1.2 Phosphodiesterase (PDE) inhibitors Segment by Type
1.2.1 Global Phosphodiesterase (PDE) inhibitors Market Value Comparison by Type (2024-2030)
1.2.2 PDE1 Selective Inhibitors
1.2.3 PDE2 Selective Inhibitors
1.2.4 PDE3 Selective Inhibitors
1.2.5 PDE4 selective inhibitors
1.2.6 PDE5 selective inhibitors
1.2.7 PDE7 selective inhibitors
1.2.8 PDE10 selective inhibitors
1.3 Phosphodiesterase (PDE) inhibitors Segment by Application
1.3.1 Global Phosphodiesterase (PDE) inhibitors Market Value by Application: (2024-2030)
1.3.2 Oral
1.3.3 Topical
1.3.4 Other
1.4 Global Phosphodiesterase (PDE) inhibitors Market Size Estimates and Forecasts
1.4.1 Global Phosphodiesterase (PDE) inhibitors Revenue 2019-2030
1.4.2 Global Phosphodiesterase (PDE) inhibitors Sales 2019-2030
1.4.3 Global Phosphodiesterase (PDE) inhibitors Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Phosphodiesterase (PDE) inhibitors Market Competition by Manufacturers
2.1 Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Manufacturers (2019-2024)
2.2 Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Phosphodiesterase (PDE) inhibitors Average Price by Manufacturers (2019-2024)
2.4 Global Phosphodiesterase (PDE) inhibitors Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Phosphodiesterase (PDE) inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Phosphodiesterase (PDE) inhibitors, Product Type & Application
2.7 Phosphodiesterase (PDE) inhibitors Market Competitive Situation and Trends
2.7.1 Phosphodiesterase (PDE) inhibitors Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Phosphodiesterase (PDE) inhibitors Players Market Share by Revenue
2.7.3 Global Phosphodiesterase (PDE) inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Phosphodiesterase (PDE) inhibitors Retrospective Market Scenario by Region
3.1 Global Phosphodiesterase (PDE) inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Phosphodiesterase (PDE) inhibitors Global Phosphodiesterase (PDE) inhibitors Sales by Region: 2019-2030
3.2.1 Global Phosphodiesterase (PDE) inhibitors Sales by Region: 2019-2024
3.2.2 Global Phosphodiesterase (PDE) inhibitors Sales by Region: 2025-2030
3.3 Global Phosphodiesterase (PDE) inhibitors Global Phosphodiesterase (PDE) inhibitors Revenue by Region: 2019-2030
3.3.1 Global Phosphodiesterase (PDE) inhibitors Revenue by Region: 2019-2024
3.3.2 Global Phosphodiesterase (PDE) inhibitors Revenue by Region: 2025-2030
3.4 North America Phosphodiesterase (PDE) inhibitors Market Facts & Figures by Country
3.4.1 North America Phosphodiesterase (PDE) inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Phosphodiesterase (PDE) inhibitors Sales by Country (2019-2030)
3.4.3 North America Phosphodiesterase (PDE) inhibitors Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Phosphodiesterase (PDE) inhibitors Market Facts & Figures by Country
3.5.1 Europe Phosphodiesterase (PDE) inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Phosphodiesterase (PDE) inhibitors Sales by Country (2019-2030)
3.5.3 Europe Phosphodiesterase (PDE) inhibitors Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Phosphodiesterase (PDE) inhibitors Market Facts & Figures by Country
3.6.1 Asia Pacific Phosphodiesterase (PDE) inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Phosphodiesterase (PDE) inhibitors Sales by Country (2019-2030)
3.6.3 Asia Pacific Phosphodiesterase (PDE) inhibitors Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Phosphodiesterase (PDE) inhibitors Market Facts & Figures by Country
3.7.1 Latin America Phosphodiesterase (PDE) inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Phosphodiesterase (PDE) inhibitors Sales by Country (2019-2030)
3.7.3 Latin America Phosphodiesterase (PDE) inhibitors Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Phosphodiesterase (PDE) inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Phosphodiesterase (PDE) inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Phosphodiesterase (PDE) inhibitors Sales by Country (2019-2030)
3.8.3 Middle East and Africa Phosphodiesterase (PDE) inhibitors Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Phosphodiesterase (PDE) inhibitors Sales by Type (2019-2030)
4.1.1 Global Phosphodiesterase (PDE) inhibitors Sales by Type (2019-2024)
4.1.2 Global Phosphodiesterase (PDE) inhibitors Sales by Type (2025-2030)
4.1.3 Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Type (2019-2030)
4.2 Global Phosphodiesterase (PDE) inhibitors Revenue by Type (2019-2030)
4.2.1 Global Phosphodiesterase (PDE) inhibitors Revenue by Type (2019-2024)
4.2.2 Global Phosphodiesterase (PDE) inhibitors Revenue by Type (2025-2030)
4.2.3 Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Type (2019-2030)
4.3 Global Phosphodiesterase (PDE) inhibitors Price by Type (2019-2030)
5 Segment by Application
5.1 Global Phosphodiesterase (PDE) inhibitors Sales by Application (2019-2030)
5.1.1 Global Phosphodiesterase (PDE) inhibitors Sales by Application (2019-2024)
5.1.2 Global Phosphodiesterase (PDE) inhibitors Sales by Application (2025-2030)
5.1.3 Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Application (2019-2030)
5.2 Global Phosphodiesterase (PDE) inhibitors Revenue by Application (2019-2030)
5.2.1 Global Phosphodiesterase (PDE) inhibitors Revenue by Application (2019-2024)
5.2.2 Global Phosphodiesterase (PDE) inhibitors Revenue by Application (2025-2030)
5.2.3 Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Application (2019-2030)
5.3 Global Phosphodiesterase (PDE) inhibitors Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bayer AG
6.1.1 Bayer AG Corporation Information
6.1.2 Bayer AG Description and Business Overview
6.1.3 Bayer AG Phosphodiesterase (PDE) inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bayer AG Phosphodiesterase (PDE) inhibitors Product Portfolio
6.1.5 Bayer AG Recent Developments/Updates
6.2 Eli Lilly and Co.
6.2.1 Eli Lilly and Co. Corporation Information
6.2.2 Eli Lilly and Co. Description and Business Overview
6.2.3 Eli Lilly and Co. Phosphodiesterase (PDE) inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Eli Lilly and Co. Phosphodiesterase (PDE) inhibitors Product Portfolio
6.2.5 Eli Lilly and Co. Recent Developments/Updates
6.3 GlaxoSmithKline Plc
6.3.1 GlaxoSmithKline Plc Corporation Information
6.3.2 GlaxoSmithKline Plc Description and Business Overview
6.3.3 GlaxoSmithKline Plc Phosphodiesterase (PDE) inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.3.4 GlaxoSmithKline Plc Phosphodiesterase (PDE) inhibitors Product Portfolio
6.3.5 GlaxoSmithKline Plc Recent Developments/Updates
6.4 Pfizer Inc.
6.4.1 Pfizer Inc. Corporation Information
6.4.2 Pfizer Inc. Description and Business Overview
6.4.3 Pfizer Inc. Phosphodiesterase (PDE) inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Inc. Phosphodiesterase (PDE) inhibitors Product Portfolio
6.4.5 Pfizer Inc. Recent Developments/Updates
6.5 Vivus Inc.
6.5.1 Vivus Inc. Corporation Information
6.5.2 Vivus Inc. Description and Business Overview
6.5.3 Vivus Inc. Phosphodiesterase (PDE) inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Vivus Inc. Phosphodiesterase (PDE) inhibitors Product Portfolio
6.5.5 Vivus Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Phosphodiesterase (PDE) inhibitors Industry Chain Analysis
7.2 Phosphodiesterase (PDE) inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Phosphodiesterase (PDE) inhibitors Production Mode & Process
7.4 Phosphodiesterase (PDE) inhibitors Sales and Marketing
7.4.1 Phosphodiesterase (PDE) inhibitors Sales Channels
7.4.2 Phosphodiesterase (PDE) inhibitors Distributors
7.5 Phosphodiesterase (PDE) inhibitors Customers
8 Phosphodiesterase (PDE) inhibitors Market Dynamics
8.1 Phosphodiesterase (PDE) inhibitors Industry Trends
8.2 Phosphodiesterase (PDE) inhibitors Market Drivers
8.3 Phosphodiesterase (PDE) inhibitors Market Challenges
8.4 Phosphodiesterase (PDE) inhibitors Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
